TW202320795A - 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法 - Google Patents

使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法 Download PDF

Info

Publication number
TW202320795A
TW202320795A TW111127690A TW111127690A TW202320795A TW 202320795 A TW202320795 A TW 202320795A TW 111127690 A TW111127690 A TW 111127690A TW 111127690 A TW111127690 A TW 111127690A TW 202320795 A TW202320795 A TW 202320795A
Authority
TW
Taiwan
Prior art keywords
cancer
week
administration
period
cycles
Prior art date
Application number
TW111127690A
Other languages
English (en)
Chinese (zh)
Inventor
布萊恩 法蘭西斯 沙利文
蘭斯 加文 萊茵
Original Assignee
美商凱爾科迪股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凱爾科迪股份有限公司 filed Critical 美商凱爾科迪股份有限公司
Publication of TW202320795A publication Critical patent/TW202320795A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111127690A 2021-07-26 2022-07-25 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法 TW202320795A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163225707P 2021-07-26 2021-07-26
US63/225,707 2021-07-26
US202163285327P 2021-12-02 2021-12-02
US63/285,327 2021-12-02

Publications (1)

Publication Number Publication Date
TW202320795A true TW202320795A (zh) 2023-06-01

Family

ID=82932627

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111127690A TW202320795A (zh) 2021-07-26 2022-07-25 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法

Country Status (11)

Country Link
US (3) US12350276B2 (cg-RX-API-DMAC7.html)
EP (1) EP4376848A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529430A (cg-RX-API-DMAC7.html)
KR (1) KR20240040768A (cg-RX-API-DMAC7.html)
AU (2) AU2022320615B2 (cg-RX-API-DMAC7.html)
CA (1) CA3227191A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000208A1 (cg-RX-API-DMAC7.html)
IL (1) IL310243A (cg-RX-API-DMAC7.html)
MX (1) MX2024001266A (cg-RX-API-DMAC7.html)
TW (1) TW202320795A (cg-RX-API-DMAC7.html)
WO (1) WO2023009438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049962A1 (en) * 2023-08-31 2025-03-06 Aadi Bioscience, Inc. Combination cancer treatments with a composition comprising an mtor pathway inhibitor
US20260053814A1 (en) * 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
JP5190271B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての5員の環付加複素環式ピリミジン
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HUE055928T2 (hu) 2014-12-17 2022-01-28 Pfizer PI3K/MTOR-inhibitorok készítményei intravénás adagolásra
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
US12109308B2 (en) 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
EP3863618A1 (en) * 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin

Also Published As

Publication number Publication date
AU2022320615B2 (en) 2025-08-21
US20260174772A1 (en) 2026-06-25
CL2024000208A1 (es) 2024-07-19
KR20240040768A (ko) 2024-03-28
EP4376848A1 (en) 2024-06-05
AU2022320615A1 (en) 2024-03-14
JP2024529430A (ja) 2024-08-06
IL310243A (en) 2024-03-01
US20230022525A1 (en) 2023-01-26
CA3227191A1 (en) 2023-02-02
WO2023009438A1 (en) 2023-02-02
US20250345342A1 (en) 2025-11-13
US12350276B2 (en) 2025-07-08
MX2024001266A (es) 2024-04-16
AU2025223785A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
JP7351888B2 (ja) 類上皮細胞腫瘍を処置する方法
US20230080409A1 (en) Biomarkers for nanoparticle compositions
JP6595024B2 (ja) B−Raf阻害薬、EGFR阻害薬及び場合によってはPI3K−α阻害薬を含む組合せ医薬
CN111032082B (zh) Her2阳性癌症的治疗
US20250345342A1 (en) Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
BR112012030909A2 (pt) métodos de tratamento de câncer pancreático
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
US20260041695A1 (en) Combination therapies for treatment of breast cancer
JP2014515390A (ja) Pi3k阻害剤化合物を用いた中皮腫の治療法
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
JP2022507686A (ja) 薬学的方法
CN117813097A (zh) 用于治疗癌症的1-(4-{[4-(二甲氨基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二吗啉-4-基-1,3,5-三嗪-2-基)苯基]脲(吉达利塞)及其组合
CN101010082A (zh) 米哚妥林用于治疗胃肠道基质瘤的用途
JP2016502974A (ja) Pi3k/akt阻害剤化合物とher3/egfr阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
US20260053814A1 (en) Treatment regimens for gedatolisib in hormonally-driven disorders
US20220071982A1 (en) Methods and uses for treating cancer
TW202532065A (zh) 治療乳癌之組合療法
HK40122790A (en) Methods and uses for treating cancer
TW202315635A (zh) 一種藥物組合及其應用